BPC-157 Half-Life: What Published Studies Report

Q: What is the half-life of BPC-157?

In the only formal preclinical pharmacokinetic study published so far (He et al., 2022), the elimination half-life of intact BPC-157 was under 30 minutes in both rats and beagle dogs after intravenous and intramuscular administration.

Q: Has the half-life of BPC-157 been measured in humans?

Not in a controlled study. A 2026 review notes that a sub-30-minute plasma half-life was also seen in a preliminary two-subject pilot, but there is no validated human pharmacokinetic profile.

Q: Why do some sources quote a much longer half-life?

They usually conflate plasma half-life with the duration of biological effects reported in animal models. Reviewers describe this as a pharmacokinetic–pharmacodynamic disconnect: the intact peptide disappears from plasma quickly, while effects in some models persist for hours or days.

Q: How is BPC-157 broken down?

Radiolabelled studies show it is rapidly cleaved into small peptide fragments and then single amino acids, which enter normal amino-acid metabolism. Excretion is mainly via urine and bile.

Q: Does a short half-life mean BPC-157 is unstable in the vial?

No. Plasma half-life reflects enzymatic degradation and clearance in a living organism. Stability of lyophilized powder or a reconstituted solution depends on temperature, light, pH, solvent and time, and has to be assessed separately.

The plasma half-life of BPC-157 is short: in the only formal preclinical pharmacokinetic study published to date, intact BPC-157 had an elimination half-life of under 30 minutes in both rats and beagle dogs (He et al., 2022). No controlled human pharmacokinetic study exists. Below we summarise what was measured, how the peptide is cleared, and why “half-life” is often misquoted.

For laboratory research use only. The compounds discussed are not approved for human or veterinary use and are not drugs, foods or cosmetics. This article summarises published research and is not medical advice.

Key points

Elimination half-life of the parent peptide: <30 min in rats and dogs, with linear (dose-proportional) kinetics.
Intramuscular bioavailability differed sharply by species: roughly 14–19% in rats versus 45–51% in dogs.
BPC-157 is cleaved into small fragments and amino acids; excretion is mainly via urine and bile.
Human data are limited to uncontrolled pilot work involving fewer than 30 people in total.
Plasma half-life says nothing about how long a vial remains stable on the bench.

Quick facts: BPC-157

Property	Value
Sequence	Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV)
Length	15 amino acids (pentadecapeptide)
Molecular formula	C₆₂H₉₈N₁₆O₂₂
Molecular weight	1419.5 g/mol (PubChem CID 9941957)
Origin	Synthetic fragment of a protein first described in gastric juice
Regulatory status	Not approved as a medicine in the US or EU; no completed Phase II trial

Lot-specific purity and identity data for our material are listed on the BPC-157 research peptide page. For a broader overview of the compound, see our BPC-157 research guide.

What the 2022 pharmacokinetic study measured

He and colleagues at the Air Force Medical University in Xi’an synthesised BPC-157 by solid-phase methods and ran the first complete absorption, distribution, metabolism and excretion (ADME) study in two species. They used a single intravenous dose, single intramuscular doses at three increasing levels, and repeated intramuscular dosing, then followed both unlabelled and tritium-labelled ([³H]) peptide.

Parameter	Rats	Beagle dogs
Elimination half-life (t_1/2) of intact peptide	<30 min	<30 min
Kinetics across tested doses	Linear	Linear
Absolute bioavailability, intramuscular	~14–19%	~45–51%
Main excretion routes	Urine and bile
Metabolic fate	Rapid cleavage to small peptide fragments, then single amino acids

Two details matter when reading this table. First, the half-life refers to the prototype (intact) peptide. Radioactivity from the label persists longer because the amino acids released by metabolism are recycled, so “total radioactivity” and “intact BPC-157” give very different curves. Second, the large species difference in bioavailability is a reminder that rodent numbers cannot simply be scaled to other organisms.

How BPC-157 is metabolised

Like most linear peptides, BPC-157 is a substrate for peptidases. Three independent lines of work describe its breakdown:

In vivo (rats and dogs): the [³H]-labelled peptide was rapidly converted into a range of small fragments and finally into free amino acids (He et al., 2022).
In vitro plasma incubation: an anti-doping laboratory in Salt Lake City found that BPC-157 forms a stable metabolite that is detectable in urine, and that the parent peptide was stable in urine samples for at least four days. Their urine method reached a detection limit of 0.1 ng/mL (Cox et al., 2017).
Stable-isotope labelling: using ¹³C/¹⁵N-labelled BPC-157, Tian and colleagues at the Shanghai Anti-Doping Laboratory identified eight metabolites formed by ordinary amide-bond cleavage plus one from a previously undescribed pathway, and validated a urine method with detection limits of 0.01–0.11 ng/mL (2023).

Reviewers also describe BPC-157 as unusually stable in gastric juice (Mateescu et al., 2026). That stability in an acidic, enzyme-rich fluid has not translated into a long circulating half-life once the peptide reaches plasma.

Half-life versus duration of effect

Many online sources quote half-lives of several hours for BPC-157. These figures do not come from pharmacokinetic measurements. A 2026 review in Pharmaceutics calls this a pharmacokinetic–pharmacodynamic disconnect: a plasma half-life under 30 minutes, confirmed preclinically and in a preliminary two-subject human pilot, contrasts with biological effects in animal models that are reported to last hours to days (Mateescu et al., 2026).

Concept	What it measures	What it does not tell you
Plasma half-life	How quickly intact peptide concentration falls in blood	How long downstream signalling lasts
Duration of effect (animal models)	How long an outcome differs from controls	How much intact peptide is still present
Detection window (anti-doping)	How long the peptide or its metabolites can be found in urine	Activity of those metabolites
Shelf life (vial)	Chemical stability of the stored material	Anything about behaviour in an organism

The same review points out that there is still no pharmaceutical-grade formulation, no permeability characterisation and no formal excipient-compatibility data for BPC-157. Formulation could change apparent half-life considerably, so any figure should always be read together with the route and vehicle used.

What is known about human data

Human evidence remains thin. A PROSPERO-registered systematic review searched four databases up to June 2026 and found three studies with 30 participants in total: two retrospective case series and one prospective intravenous safety pilot with two participants. All three were judged to be of poor methodological quality, and the certainty of evidence was rated very low (Poolton et al., 2026). None of these studies provides a validated human pharmacokinetic profile. Our separate summary of BPC-157 human research covers them in more detail.

Handling in the lab: stability is a separate question

A short biological half-life is sometimes mistaken for poor shelf stability. The two are unrelated. In plasma, BPC-157 is exposed to peptidases at 37 °C; in a sealed vial, degradation is driven mainly by moisture, temperature, light, oxidation and pH.

Lyophilized powder: store sealed, protected from light, at −20 °C for long-term storage. See our guide to storing lyophilized peptides.
Reconstituted solution: keep at 2–8 °C, avoid repeated freeze–thaw cycles and record the date of reconstitution. We are not aware of a peer-reviewed stability study of BPC-157 in bacteriostatic water, so any in-use period should be confirmed for your own conditions, for example by HPLC. See does BPC-157 need to be refrigerated?
Concentration: to work out the concentration after adding a given volume of diluent, use the peptide reconstitution calculator; the general procedure is covered in how to reconstitute peptides.

Related research

BPC-157 vs TB-500: structure and research compared
BPC-157 arginate vs acetate salt forms
How BPC-157 purity is tested

Frequently asked questions

What is the half-life of BPC-157?